It’s an environment of rapidly increasing clinical trials: ClinTrials records 262,000 trials open by December 2017.
Despite only nine CROs running ~60% of all outsourced clinical research, there isn’t an obvious increasing efficiency in the development process. In a JCO article by a 26 – year old resident doctor at the end of life care of a 21- year old lady, he quoted Haas The Servant Song, and this struck a chord that it’s easy to forget why we are working in clinical trials: human beings need to care for one another
We are pilgrims on a journey,
We are brothers on the road
We are here to help each other
Walk the mile and bear the load
The CRO industry promotes approaches such as risk-based monitoring and a claimed focus on patient centricity, but humans still run clinical trials. Do many site staff enjoy the current approaches to clinical trials? Many patients are not convinced to join. Trials that enrol more slowly than the plan usually cost more money in CRO time and can have negative impact on the sponsor company in the investment community.
Could they even go faster than an often conservative CRO plan?
Delays in development ultimately delay the time to the sale of the assets, making delay very costly in opportunity costs.
Gaea uses the elephant as its symbol, as Nigel Goodman, the General Director, is passionate to conserve this iconic species: natures’ gardener, under immense pressure of extinction. The Matriarch of an elephant family shares her experience for the success of her family. Nigel Goodman, the Gaea General Director, as a veteran of the pharma, biotech, CRO and consulting industries is happy to share his experience to bring products through clinical development as effectively as possible, as a provider for the sponsor, so that protocol questions can be answered and the development can move on.